- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04179500
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers (PaSEM)
An Open-Label Phase 2 Trial to Evaluate the Male Reproductive Safety of a 6-Month Combination Treatment for Pulmonary Tuberculosis (TB) of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) in Adult Male Participants With Drug Resistant Pulmonary TB
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to assess the male reproductive safety of pretomanid in the regimen (BPaMZ) of bedaquiline 200mg (200mg daily for 8 weeks then 100 mg daily for 18 weeks), together with pretomanid 200 mg (1x daily) + moxifloxacin 400 mg (1x daily) + pyrazinamide 1500 mg (1 x daily) for 26 weeks in participants with drug-resistant pulmonary tuberculosis (DR-TB).
The secondary objective of the study is to evaluate the tuberculosis (TB) treatment efficacy, safety and tolerability after 26 weeks of active treatment for TB and follow up until 52 weeks after end of the above-described treatment regimen in participants with DR-TB.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Joanna Moreira
- Phone Number: 1 (646) 616-8621
- Email: Joanna.Moreira@tballiance.org
Study Contact Backup
- Name: Paul Bruinenberg, MD, MBA
- Phone Number: +1 646-616-8629
- Email: Paul.Bruinenberg@tballiance.org
Study Locations
-
-
-
Tbilisi, Georgia
- National Center for Tuberculosis and Lung Diseases
-
-
-
-
-
Johannesburg, South Africa
- CHRU, Sizwe Tropical Diseases Hospital
-
Port Elizabeth, South Africa
- Isango Lethemba TB Research Unit Empilweni TB Hospital
-
Rustenburg, South Africa
- The Aurum Institute: Rustenburg Clinical Research Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures.
- Male gender 18 years or over
- Body weight (in light clothing and no shoes) ≥ 45kg.
- A positive molecular test for tuberculosis in sputum either at screening or within one month prior to enrolment.
Disease Characteristics:
- Participants must have been diagnosed with TB prior to or at screening
- Participants' TB should be resistant to rifampicin and/or isoniazid, and susceptible to fluoroquinolones by rapid sputum-based tests.
- Participants who have had previous treatment for DR-TB for more than 3 months at start of screening should be discussed with the medical monitor.
- A chest x-ray, within 26 weeks prior to or at the screening visit, which in the opinion of the Investigator is compatible with pulmonary TB
Exclusion criteria:
- Resistant to fluoroquinolones by rapid molecular test
- History of male infertility or vasectomy
- Unable to produce semen sample
- Evidence at screening of azoospermia
- Known erectile dysfunction that would prevent ejaculation.
- Historical or active disease process of the male reproductive tract that would compromise sperm production. e.g. tuberculous epididymitis.
- History of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
For HIV infected participants any of the following:
- CD4+ count <100 cells/μL
- Received intravenous antifungal medication within the last 90 days
- Participants with newly diagnosed tuberculosis and HIV that require initiation of appropriate HIV therapy before participants has received at least 2 weeks of an antituberculosis regimen.
- Received pretomanid and/or delamanid to treat TB
- Known chronic hepatitis B or C
For HIV infected participants:
- The following antiretroviral therapy (ART) should not be used:
1. Stavudine 2. Zidovudine 3. Didanosine 4. Triple NRTI regimen is not considered optimal for HIV treatment (poor efficacy)
13. Participants with the following toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Disease (DMID) adult toxicity table (Draft November 2007) where applicable:
- Platelets <75,000/mm3
- Creatinine >1.5 times upper limit of normal (ULN)
- eGFR ≤ 60 mL/min
- Haemoglobin <8.0 g/dL
- Serum potassium less than the lower limit of normal for the laboratory. This may be repeated once
AST:
- ≥3.0 x ULN to be excluded
- results between 1.5 x ULN and 3 x ULN must be discussed with and approved by the Sponsor Medical Monitor
ALT:
- ≥3.0 x ULN to be excluded
- greater than ULN must be discussed with and approved by the Sponsor Medical Monitor
ALP:
- ≥3.0 x ULN to be excluded
- 2.0 - <3.0 x ULN must be discussed with and approved by the Sponsor Medical Monitor
Total bilirubin:
- >1.5 x ULN to be excluded
- Greater than ULN must be discussed with and approved by the Sponsor Medical Monitor
Direct bilirubin:
• greater than 1x ULN to be excluded
- Positive hepatitis B surface Ag, or hepatitis C antibody
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Participants
Participants will receive bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg once daily (BPaMZ) for 26 weeks.
|
pretomanid 200 mg (once daily) for 26 weeks (with meal)
Other Names:
bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Sperm Number - Week 26
Time Frame: Week 26
|
Change from baseline in total sperm number at 26 weeks of therapy.
|
Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Sperm Number - Week 13 and Week 44
Time Frame: Week 13 to Week 44
|
Change from baseline in total sperm number at 13 weeks of therapy and at 18 weeks post end of therapy.
|
Week 13 to Week 44
|
Change in Male Reproductive Hormones
Time Frame: Up to Week 78
|
The change from baseline in Male reproductive hormones at Week 2, 4, 8, 12, 16, 35, 44, 52, 65, 78 and at early withdrawal.
Reproductive hormones: luteinizing hormone (LH), follicle-stimulating hormone (FSH), Inhibin B and Testosterone.
|
Up to Week 78
|
Collaborators and Investigators
Investigators
- Study Chair: Antonio Lombardi, MD, Global Alliance for TB Drug Development
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Antitubercular Agents
- Moxifloxacin
- Bedaquiline
- Pyrazinamide
Other Study ID Numbers
- Pa-824-CL-012
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Pretomanid
-
Global Alliance for TB Drug DevelopmentCompletedMulti-drug Resistant TuberculosisUnited States
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingBiodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PETTuberculosisUnited States
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingTuberculosis | Rifampicin Resistant TuberculosisBrazil, India, South Africa, Tanzania, Thailand
-
Tuberculosis Research Centre, IndiaInternational Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable... and other collaboratorsActive, not recruitingPre-Extensively Drug-Resistant Pulmonary TB | Treatment Intolerant Multidrug-Resistant Pulmonary TB | Non-responsive Multidrug-Resistant Pulmonary TBIndia
-
Global Alliance for TB Drug DevelopmentCompleted
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Extensively Drug-Resistant Tuberculosis | Tuberculosis, MDR | XDR-TB | Pre-XDR-TBSouth Africa, Russian Federation, Georgia, Moldova, Republic of
-
Global Alliance for TB Drug DevelopmentRecruitingDrug Sensitive Tuberculosis | Pulmonary Tuberculosis | Pulmonary TBPhilippines, South Africa, Tanzania, Georgia, Uganda
-
Bill & Melinda Gates Medical Research InstituteGlobal Alliance for TB Drug Development; Janssen Pharmaceutica; Otsuka Pharmaceutical...RecruitingPulmonary TuberculosisPhilippines, South Africa
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsActive, not recruitingMulti-drug Resistant Tuberculosis | Pulmonary Tuberculosis | Extensively Drug-Resistant TuberculosisBelarus, South Africa
-
The Aurum Institute NPCLudwig-Maximilians - University of Munich; Global Alliance for TB Drug Development and other collaboratorsRecruitingTuberculosisSouth Africa, Mozambique, Tanzania